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ABSTRACT  
Cubosomes are square and rounded particles with internal cubic lattice. Cubosomes are thermodynamically stable and consist of honeycombed 
(cavernous) structures separating two internal aqueous channels and a large interfacial area. Cubosomes are nanoparticles which are self 
assembled liquid crystalline particles of certain surfactants with proper ratio of water with microstructure that provides unique properties of 
practical interest. Bicontinuous cubic liquid crystalline phase is optically clear and very viscous material has the unique structure at nanometer 
scale. The word bicontinuous refers to the division of the two continuous but non-intersecting aqueous regions by lipid bilayer that is twisted 
into space filling structure. Hydrating a surfactant or polar lipid that forms cubic phase and then dispersing a solid like phase into smaller 
particles usually forms a cubosomes. Self-assembled cubosomes as active drug delivery systems are receiving more and more attention and 
interest after the first discovery and nomination. They exhibit different internal cubic structure and composition with different drug-loading 
modalities. It has high internal surface area and cubic crystalline structures, relatively simple preparation method, biodegradability of lipids, 
the ability of encapsulating hydrophobic, hydrophilic and amphiphilic substances, targeting and controlled release of bioactive agents. 
Cubosomes are having wide range of applications in various fields and they can be characterized by various evaluation parameters. So, 
Cubosomes are gaining more attention in pharmaceutical field.  
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A drug delivery system is a device that safely brings a 
therapeutic agent to the specific body site at a certain rate to 
achieve an effective concentration at the site of drug action. 
The release of drug in a predesigned manner is termed 
controlled drug release (CR), which is used to promote 
therapeutic benefits while minimizing toxic side-effects. 
Sustained release over an extended period of time may 
reduce the need for multiple dosing which will be a benefit in 
terms of reduced cost and increased patient compliance [1-
3]. To achieve targeted drug delivery by encapsulating the 
drug within vesicular structure such a system is known to be 
vesicular drug delivery system. In this system if the vesicles 
behave as carrier system it will transport high molecular 
weight of drugs, and if behave as penetration enhancer it will 
increase the drug transport rate across the skin [4, 5]. There 
are huge number of vesicular drug delivery systems that 
allow drug targeting and the sustained or controlled release 
of conventional medicines. In such a system cubosomes are 
also part of the vesicular drug delivery system or lipid based 
colloidal system which were discovered in 1980 [4, 5]. The 
term “Cubosomes” were coined by Larsson that reflects the 
cubic molecular crystallography and similarity to liposomes 
[6, 7]. 
Cubosomes are distinct, sub-micron, nano-structured 
particles of bicontinuous cubic liquid crystalline phase [7, 8]. 
Cubosomes are nanoparticles which are self assembled 
liquid crystalline particles of certain surfactants with proper 
ratio of water with microstructure and also posses as solid 
like rheology [9]. Cubosomes possess the same 
microstructure as the parent cubic phase but have larger 
specific surface area and their dispersions have much lower 
viscosity in comparison to the bulk cubic phase [7, 10]. Bulk 
cubic phases have higher viscosity than cubosomal 
dispersion [11-13]. Most concentrated surfactants that form 
cubic liquid crystals lose these phases to micelle formation at 
high dilutions, due to optimal water insolubility. Their cubic 
phases exist in equilibrium with excess water and can be 
dispersed to form cubosomes. Cubosomes are typically 
produced by high-energy dispersion of bulk cubic phase, 
followed by colloidal stabilization using polymeric 
surfactants. One application of cubic phase liquid crystals is 
the controlled release of selected water-oil soluble 
molecules. The emulsification of cubic lipid phases in water 
results in the production of cubosomes that can be defined as 
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nanoparticle disperse systems characterized by high 
biocompatibility and bioadhesivity [14-16]. Cubosomes are 
composed of lipids, surfactants and polymer molecules 
which have both polar and non polar components, termed as 
amphiphilic. The hydrophobic effect drives amphiphilic 
molecules in polar solvents to spontaneously self assembling 
into an array of thermodynamically stable liquid crystalline 
phases with lengths on nanometer scale [17]. Thus, 
cubosomes are bicontinuous cubic liquid phase enclosing 
two separate regions of water divided by surfactant 
controlled bilayers [7]. Bicontinuous cubic phases are 
optically isotropic, very viscous and solid like liquid 
crystalline substance having cubic crystallographic 
symmetry [17]. Cubosomes have great importance in 
nanodrug formulations [7]. 
2. Structure of Cubosomes 
The basic structure of cubosomes includes honeycombed 
structures separating the two internal aqueous channels 
along with large interfacial area [Fig 1] [12]. Amphiphilic 
molecules form bicontinuous water and oil channels, where 
“bicontinuous” refers to two distinct (continuous, but non-
intersecting) hydrophilic regions separated by the bilayer 
[12]. The structure generally maintains the efficacy; stability 
of actives such as vitamins and proteins. In the structure, 
surfactants assembles into bilayers that are twisted into a 
three dimension, periodic, minimal surface forming tightly 
packed structure, like “honeycombed” with bicontinuous 
domains of water and lipid. Its structure is different from 
liposomes because its can accommodate water-soluble, lipid 
soluble and amphiphilic molecules [18]. The inter-
connectiveness of the structure results in a clear viscous gel 
that is similar in appearance and rheology to cross-linked 
polymer hydrogels. Monoglyceride-based cubic gels possess 
long range order than hydrogels and their composition (i.e., 
lipid and water) gives excellent biocompatibility [12]. 
 
 
Figure 1: Structure of Cubosome. 
 
2.1 Types of Cubosomes 
2.1.1. Liquid Cubosome Precursors: The hydrotrope 
dilution process is found to produce more stable and smaller 
cubosomes. Nucleation process allows the formation of 
particles whose growth is seen under crystallization and 
precipitation processes. Monoolein is properly dissolved in a 
hydrotrope, such as ethanol, that prevents it from liquid 
crystalline formation. Thus, dilution of this mixture 
spontaneously “crystallizes” or precipitates the cubosomes. 
Quid precursor process is allowed for easier scale up of 
cubosome preparations and avoids the bulk solids handling 
and potentially damaging high energy processes [19, 20]. 
2.1.1 Powdered Cubosome Precursor:  
Powdered cubosome precursors are composed of 
dehydrated surfactant coated with polymer. Such powders 
offer advantages to liquid phase hydrotropic cubosome 
precursors.  Cubosomes with a mean particle size of 600 nm 
are formed by the hydration of the precursor powders, as 
confirmed by light scattering and cryo-TEM [10]. Cubosomes 
which are made up with the use of lipids are waxy and sticky 
solids. Coating of the waxy lipid on water-soluble non-
cohesive starch generally prevents from agglomeration and 
controls the size of the particle. An excellent process for his 
purpose is spray drying. [20]. 
3. Structural components of cubosomes 
3.1. Amphiphilic lipids 
The widely used amphiphilic lipids to prepare cubosomes 
are gyceryl monooleate GMO, usually discussed to as 
monoolein and phytantriol (PHYT) [21, 22]. GMO consists of 
mixture of the glycerides of oleic acid and other fatty acids, 
containing mostly of monooleate which fits to the group of 
amphiphilic lipids with capacity to form various lyotropic 
liquid crystals [23, 24]. It has been reported that GMO with 
hydrocarbon chain length in the range of 12-22 have greater 
tendency to form cubic phases [25].  Further, GMO is a 
biocompatible and biodegradable material under as 
generally recognized as safe (GRAS) category by FDA, mainly 
used as emulsifier in the food industry. PHYT is a material 
with a phytanyl chain, also exhibit the formation of cubic 
phases upon increasing the water content. PHYT, chemically 
3,7,11,15-tetramethyl-1,2,3-hexadecanetriol, is a frequently 
used component in cosmetic products. It has been 
recommended as a good alternate for GMO in the 
manufacturing of cubosomes. As compared to GMO, PHYT 
has an added advantage that it shows greater structural 
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stability. The GMO are more prone to ester hydrolysis [26]. 
Although PHYT and GMO have different molecular 
structures, these two materials show much related phase 
transition behaviors with increasing water content and 
temperature.  
3.2. Stabilizers 
The research scientists have suggested an important role for 
the surfactants as stabilizers for improved stability of 
cubosomes against coalescence to the bulk cubic phase. 
Poloxamer 407 (P407), a PEO-PPO-PEO tri-block copolymer, 
is mostly investigated surfactant in the preparation of 
cubosomes with its PPO portions being located either at the 
surface of the cubosomes or within the bilayer structure, 
whereas the PEO chains are exposed to the surrounding 
water phase [27, 28]. P407 is usually applied upto a 
concentration of 20 %w/w depending on the quantity of 
dispersed phase. Wadsten-Hindrichsen et al. [29] 
investigated the effect of three water-miscible solvents i.e 
propylene glycol (PG), polyethylene glycol 400 (PEG400) 
and 2-meth-yl-2,4-pentanediol (MPD) on a PHYT-based 
cubosomal system. They showed that MPD produced a 
sponge phase whereas with the two other solvents, PG and 
PEG400, only cubic, lamellar and non-ordered liquid phases 
were identified. The main reasons attributed for difference 
in phase behavior were more hydrophobic nature of PHYT 
as compared to GMO and the branched hydrocarbon chain of 
PHYT, which makes PHYT less flexible than GMO. 
On substituting b-casein with P407 as the stabilizer to GMO 
and PHYT based cubosomes, its internal structure as well as 
its morphology was studied [30]. A Pn3 m phase structure 
was displaced by the GMO-b-casein cubosomes  and at 60˚C 
a QII to HII phase transition .Whereas, Im3 m phase 
structure has P407-GMO dispersion and at higher 
temperatures, that is, 70˚C the HII phase gets appeared. The 
concentration of the stabilizer and the Pn3m phase structure 
was detected in the case of PHYT systems. P407-PHYT 
dispersion displayed only a direct QII to La conversion, 
whereas upon heating the b-casein-PHYT system displayed a 
QII to HII to La transition behavior. Steric stabilization to 
dispersions of lipid nanostructured particles gives the b-
casein and Im3m structure in nanoparticles avoids the 
transition. In cubosomes, it was discovered that the poly 
(ethylene oxide) stearate stabilizers (commercially known 
as Myrj) were more effective as steric stabilizers. In contrast, 
Myrj 59 was proven to be more effective than P407 for PHYT 
cubosomes with an average of 100 poly (ethylene oxide) 
units at a concentration of fivefold lower than that of P407 
[46]. To GMO-based cubosomes with P407 the 
hydroxypropyl methylcellulose acetate succinate (HPMCAS) 
showed roughly equal stability [31]. 
4. Advantages and limitations of cubosomes: 
4.1. Advantages of cubosomes 
1. They have ability to encapsulate both hydrophilic and 
hydrophobic also amphiphilic drugs. 
2. They have a sustained- release drug delivery 
characteristics. 
3. Cubosomes have biocompatibility and bioadhesivity 
properties. 
4. Bicontinuous cubic liquid crystalline phase of cubosomes 
even stable in excess water [32]. 
5. Cubic phase materials can be formed by simple 
combination of biologically compatible lipids and water and 
are thus well suited for use in treatments of skin, hair, and 
other body tissue. 
6. With respect to liposomes, cubosomes possesses a larger 
ratio between the bilayer area and the  particle volume and a 
larger breaking resistance [33] 
7. Because of their high internal surface area and crystalline 
cubic structures they have high drug payloads. 
8. They can be prepared by simple method and possess lipid 
biodegradability [34, 35]. 
9. Targeted release and controlled release of bioactive 
agents [7]. 
10. Cubosomes are excellent solubilizers, compared with 
conventional lipid or non-lipid carriers. 
11. They show high drug carrier capacity for a range of 
sparingly water-soluble drugs. 
12. These are an excellent vehicle to protect the sensitive 
drug from enzymatic degradation and in-vivo degradation, 
such as peptides and proteins. 
13. The cuboidal system enhances the bioavailability range 
twenty to more than one hundred times of water-soluble 
peptides [36].  
14. The cubic phases of cubosomes can be fractured and 
dispersed to form particulate dispersions that are colloidally 
and/or thermodynamically stable for longer time [7]. 
4.2. Limitation of cubosomes as a drug carrier 
1. Cubosomes may lead to low drug loading efficiency and 
drug leakage in preparation, preservation and transport in 
vivo, thus the major problem of their stability acts as a 
barrier and thus limiting their use [37]. 
2. Large scale production is sometimes difficult because of 
high viscosity [7]. 
5. Manufacturing of Cubosomes 
Cubosomes can be manufactured by two distinct methods: 
5.1 Top down approach: In the research area they are the 
most widely used methods. It was reported in 1996 by 
Ljusberg-Wahren [Fig 2]. The viscous bulk cubic phase is 
prepared by mixing the lipids with stabilizers; by the input 
of high energy (such as High-Pressure Homogenization 
[HPH], sonication or shearing) the resultant mixture is 
dispersed into aqueous solution to form Lyotropic Liquid 
Crystal (LLC) nanoparticles. A clear rigid gel formed by 
water-swollen cross-linked polymer chains that resembles 
the bulk cubic phase. In the preparation of LLC 
nanoparticles, HPH is the most widely used technique. In 
top-down approach, cubosomes are prepared and observed 
to co-exist with vesicles (dispersed nanoparticles of lamellar 
liquid crystalline phase) or vesicle-like structures [35].  
 
Figure 2: Cubosomes by Top down Technique. 
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5.2 Bottom up approach: In the bottom-up approach it 
forms the nanostructure building blocks and then assembles 
them into the final material [Fig 3]. In water insoluble lipids 
the hydrotrope gets dissolves so as to create a liquid 
precursors. Less energy input is needed at high 
concentration to prevent the formation of liquid crystals. 
Dispersing inverse micellar phase droplets leads to the 
formation of cubosomes in water at 80℃ and allow them to 
slowly cool and droplets get crystallizes to cubosomes. 
Monoolein-ethanol solution is diluted with aqueous 
poloxamer 407 solution produced by cubosomes at room 
temperature. Thus cubosomes are formed by emulsification. 
The bottom-up approach cannot avoid the forming of 
vesicles through cryo-TEM, many vesicles and vesicle-like 




Figure 3: Cubosomes by Bottom up Technique. 
 
6. Characterization of drug release from 
cubosomes 
 For maintaining the concentrations of the drug in the 
therapeutic concentration range for a prolonged period of 
time, the sustained release drug delivery systems are 
beneficial. It helps in the reductions of frequency of drug 
administration and avoids hazardous side effects. Based on 
the two main rationales ,the cubosomes have been proposed 
as a delivery system for drugs and other bioactive agents:  
 solubilization of poorly water-soluble drugs  
 controlled or sustained release of the loaded drugs  
The release of drugs of various molecular weights and 
polarities are controlled and incorporated by the cubic 
phase. Higuchi-type diffusion-controlled kinetics is obeyed 
by the cubic phase matrix from where the drug releases and 
shows  a linear dependence upon the square root of time 
where diffusion is out of the matrix. 
During the diffusion of incorporated drugs, their surface 
area generally enlarges because of the bulk cubic phase that 
gets divided into dispersed nanostructured particles as 
cubosomes . On division the main properties of cubic phase 
(i.e. solubility, drug loading and diffusion of drug through the 
cubic matrix) are not expected to change into cubosomes. 
The cubosomes with a surface area of a diameter of about 
200nm which is actually 200 000 times much more greater 
than the equivalent cubic part of cubic phase, have greater 
diffusion rate of the drug. In controlled-release system, it is 
difficult to apply it directly because of the nanoscale size of 
the cubosomes [38]. To prevent rapid drug release their 
charge, viscosity and structure seems to be very useful. The 
physicochemical properties of the drug, swelling capacity, 
interaction between the nanocarrier and active agent, 
structure and composition of the lipid bilayers, all depends 
on their release profile. From cubosomes, Lai et al. [39] 
studied the release of simvastatin, which is a hydrophobic 
active. In gastric and intestinal fluids the simvastatin crystal 
simulated a rapid release of more than 90% at 1hr and in the 
same medium at 10hr the cubosomes were released to less 
than 3% of simvastatin. In the cubic matrix the hydrophobic 
portion shows the high affinity of simvastatin that prevents 
the drug from escaping into the nanostructured particles. 
The two different cubosomes, prepared from GMO and 
PHYT, where studied by Lee et al. [40]. Various molecular 
weights were evaluated for several model hydrophilic drugs 
for in-vitro release kinetics and matrix was thus changed 
from QII GMO to QII PHYT that release the rates of drug 
which got decreased . The sustained release of cinnarizine 
over 48 h after oral administration to rats were 
demonstrated by cubosomes formed from PHYT was 
reported by Nguyen et al. [41]  . When the cubosomes were 
prepared by using GMO, its drug plasma concentrations fell 
below  after 24 hr . The incorporation of some small and 
large molecules whose enlarged size on release profile from 
the cubic phase of GMO was investigated by the Clogston et 
al. [42]. Thus, when the size of the added compound 
increases the rate of release decreases. Rubipy and 
tryptophan,  are considered as small molecules whose 
release from the cubic phase over a period of time is 1–3 
days, whereas cytochrome c, lysozyme and myoglobin, 
which are mid-sized molecules, they generally occur in a 
week. Ovalbumin, conalbumin, apo-ferritin and calf thymus 
DNA, are the large macromolecules which occur in 3 weeks 
with less than 12% of the compound. 
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Figure 4: Action of Cubosomes incorporated drugs on tumors. 
 
7. Opportunity for improvement of loading and 
release behavior of cubosomes through 
functionalization  
The loading of drugs in nanocarriers and/or the release 
behavior of loaded drugs are controlled by modifying the 
cubosomes with concept of functionalization. As most of the 
carrier is occupied by water, the loading of water soluble 
molecules becomes challenging due to relatively fast drug 
leakage. Surfactants serving as anchors there, 
functionalization of cubosomes can be achieved by 
integrating into the liquid crystal–the hydrophilic channels 
are attracted to the hydrophilic part while hydrophobic 
segment further penetrates into the bilayers of the structure. 
Surfactant interaction with the hydrophilic drugs can be 
controlled by adjusting the hydrophilic segments. For 
example, the loading of an oppositely charged active can be 
enhanced by a charged part thus the loaded active leads to 
slower release. Into the LLC, the loading of water-soluble 
ketoprofen with negative charge was enhanced by using 
surfactants of positive charge such as dimethyl ammonium 
chloride, dioctadecyl dimethyl ammonium chloride and 
dioctadecyl ammonium chloride [43]. The amount of 
surfactant added for functionalization is critical one because, 
larger amount can change the cubic phase into lamellar 
phase. Gurfinkel et al reported that if the concentration of 
oleyl lactate (OL) is increased, it will affect the lipid packing 
as well as hydrate the head groups. At low concentration the 
cubic phase was formed, whereas at higher concentration the 
hexagonal phase was preferred [43]. 
The matrix of cubic phase is affected by the location of the 
surfactants. Although within the lipid bilayer the more 
lipophilic types prefers to stay, thus leading to the formation 
of lamellar phase, also at its interfacial area the more polar 
types locates which directs the formation of reverse 
hexagonal phase [44]. In this way, a functionalizing 
surfactant molecule must have reachable hydrophilic part, 
low water solubility and Krafft temperature, and critical 
packing parameter (head-to-tail volume ratio) equal to unity. 
Liu et al. [45] showed that the phase transition from cubic 
phase to lamellar phase of PHYT occurs when the curvature 
of the self-assembled system toward the hydrophobic section 
increased and the ionic surfactant content increases. 
Similarly, when the phase transition from lamellar phase to 
cubic phase occurs, it occurs between the head groups of the 
ionic surfactant where the ionic strength increased leading to 
the decrease in the repulsion. Because of various 
hydrophilic-lipophilic balance (HLB) values the cubic-phase-
based drug delivery system is crucial for the selection of 
additives. By varying the polarity of the additives the phase 
behavior of GMO was studied [46]. To improve the efficiency 
of GMO-based drug delivery systems the additives were 
added with low HLB that promoted higher and faster 
transformation into the cubic phase upon hydration. Thus, 
for bioadhesive formulations, the lamellar phase with 
additives of high HLB induces the formation of GMO. When 
large amphiphilic polymers or ‘tethers’ are employed into 
the matrix of cubosomes they leads to the approaches of the 
functionalization. Not just on the surface of the cubosomes 
and on the internal bilayers of the cubic matrix, Landh [47] 
used large amounts of P407 to incorporate into it. Most of 
the polymers adhere to the surface of the particles at low 
concentrations of P407 as proven ; whereas the phase 
transition  occur from Pn3m to Im3m at higher concentration 
and without destroying it the P407 get inserted into the bulk 
of the cubic matrix [48]. By using a layer-by-layer approach, 
the seven polyelectrolyte were prepared with polymer-
coated cubosomes and the burst-release was effectively able 
to  reduce associated with fluorescein-loaded cubosome [49]. 
Also, pH-sensitive GMO based cubic phase was developed 
when complex coacervation were taken between 
hydrophobically modified alginate and hydrophobically 
modified silk fibroin in the water channels [50].The water 
channels of the cubic phase were blocked by coacervate 
under low pH  and thus release is  prevented. With  a higher 
release, the dissolution of the coacervate results from the 
higher medium. The initial release rate of a hydrophilic drug 
from GMO-based cubosomes is retarded through adsorption 
of a layer of cationic poly-e-lysine by simple surface 
modification [51]. By incorporating lipopolymers, the 
internal nanostructures of cubosomes in hydrophilic 
domains can be functionalized. of can be functionalized. In 
the water–PHYT inter-facial area the lipopolymers can be 
incorporated by the PEGylation of the cubosomes using 
DSPE-mPEGs, thus the internal structures of the 
nanoparticles gives major effect when induced [52].The 
internal cubic phases of hydrophilic nanochannels are 
enlarged due to the presence of DSPE-mPEGs. Therefore, the 
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modification of cubic dispersions is an attractive approach 
for these PEGylated lipids. 
8. Application of Cubosomes  
8.1. Controlled release of drugs: Control release of 
solubilised substance is the most popular application of 
cubosomes. Cubic phase is more applicable for control 
release because of its small pore size (5-10nm), ability to 
solubilize hydrophilic, hydrophobic, amphiphilic molecules 
and its biodegradability by simple enzymes [Table 1] [53].
 
Table 1: List of drugs incorporated in Cubosome for Sustained drug delivery system [12] 
S.  No.      Researcher           Drug        Category Associated Disease 
   1.    Engstrom et al,        2-amino-1- 
  phenylpropanol HCl 
    Antidepressant  Mania, Depression 
      Nitroglycerin      Anti-anginal    Angina pectoris 
          Oestriol   Hormonal therapy Atrophic vaginitis, 
         Pruritus 
   2.     Sadhale et al.         Cefazolin        Antibiotics    Genito-urinary,  
  respiratory track 
        infection 
       Cefuroxime        Antibiotics   Meningitis bone and soft 
tissue infection 
         Prilocaine    Local anesthetic       In Destistry 
   3.       Damani        Clindamycin  
         phosphate 
        Antibiotics Pertonitis, Staphylococcal 
bone and joint infection 
   4.    Engstrom et al.       Clomethiazole       Psychotropic          Insomnia 
   5.    Engstrom et al.        Clotrimazole         Antifungal  Vagina, mouth and 
     skin infection 
   6.    Engstrom et al.         Gramicidin     Topical steriod    Corticosteroid  sensitive 
dermatoses 
            Insulin      Hypo/Hyper  
      glycaemics 
   Diabetes mellitus 
   7.      Neilsen et al.       Indomethacin         NSAIDS Gout, rheumatoid arthritis 
Isosorbidemononitrate       Anti-anginal Angina pectoris 
         Lidocaine   
      hydrochloride 
    Oral prepration   Fungal infection 
   of external ear 
   8.            Boyd           Diazepam  Sedative-hypnotic       Anxiety, insomnia, 
seizures 
         Rifampicin       Bactericidal    
        antibiotic 
      Tuberculosis 
         Griseofulvin        Antifungal      Fungal infection  
            of skin 
            Propofol          Hypnotic      Procedural sedation, to 
induce and maintain 
General Anesthesia 
 
8.2. Melanoma (cancer) therapy: Recently few anticancer 
drugs have been successfully encapsulated in cubosomes 
and characterized physicochemically [Fig 4]. The unique 
structure of this promising nanocarrier suggests its 
application in melanoma therapy [54]. 
8.3. Oral drug delivery: Cubosomes address the varied 
challenges in oral delivery of numerous promising 
compounds including poor aqueous solubility, poor 
absorption and large molecular size. These are both liquid 
and powder in capsule product comprising our self 
emulsifying liquid crystalline nanoparticles technology 
(LCNP). In an alternative application large proteins have 
been encapsulated for local activity in gastrointestinal track. 
Liquid crystalline nanoparticles technology carriers can be 
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combined with controlled release and targeting 
functionalities. The particles are designed to form in situ in a 
controlled rate, which enables an effective in vivo 
distribution of the drug. Liquid crystalline nanoparticles 
technology carriers can also be released at different 
absorption sites, for example in upper or lower intestine, 
which is important for the drugs that have narrow regional 
absorption window [55]. 
8.4. Intravenous drug delivery systems: Lipid 
nanoparticles comprising interior liquid crystal structures of 
curved lipid membranes are used to solubilize encapsulate 
and deliver medications to disease areas within the body. 
While emulsions and liposomes have found use as 
intravenous carriers in drug products, liquid crystal 
nanoparticle structures increased payloads of peptides, 
proteins and many insoluble small molecules and are ideal 
carriers for injection or infusion of many actives [1]. 
8.5. Topical drug delivery systems: Cubic phases are more 
bioadhesive in nature, so that they can conveniently use in 
topical and mucosal depositions and delivery of different 
drugs. Topical delivery systems are based on the 
exploitation of unique properties of liquid crystal (LC) and 
liquid crystal nanoparticle technologies (LCNT). Topical 
drug delivery systems are unique in situ forming 
bioadhesive LC systems facilitate controlled and effective 
drug delivery to mucosal surfaces (buccal, ophthalmic, 
vaginal and others). This fascinating system forms a thin 
surface film at mucosal surfaces consisting of a liquid crystal 
matrix which nanostructure can be controlled for achieving 
an optimal delivery profile and provides good temporary 
protection of sore and sensitive skin [56, 57]. 
9. Conclusion 
Bicontinuous cubic liquid crystalline phases, either in bulk 
or cubosome form, offer unique properties of particular 
interest to the personal care industry. Cubic phase materials 
can be formed by simple combination of biologically 
compatible lipids and water and are well used in the 
treatments of skin, hair, and other body tissue. The main 
application of cubosomes are in melanoma (cancer) therapy, 
oral drug delivery systems, intravenous drug delivery 
systems and topical drug delivery systems. The ability to 
form cubosomes during formulation, or during manufacture 
offers great flexibility in the product development. 
Cubosomes which are prepared in dispersion possess a 
nanometer scale structure identical to the bulk cubic phase. 
The bulk cubic phase has sufficient length scale to allow 
controlled release of solutes. Formulation of personal care 
products containing cubosomes often requires additional 
surface-active ingredients. Some observations of skin 
irritation by bulk cubic phase generally used to avoid 
residual oleic acid. It is expected that in the next 10 to 20 
years, cubosomes containing protein and peptide based 
drugs will constitute more than half of the new drugs 
introduced into the market and more than 80% of these 
protein drugs will be antibodies due to control release 
activity. Further specialized studies are required to confirm 
this fascinating hypothesis and to better investigate the role 
of vesicles and cubosomes in controlling the release of the 
drug. 
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